A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Placebo-Controlled
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2016
At a glance
- Drugs AZD 5213 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions
- Sponsors AstraZeneca
- 18 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.